



2014 Annual General Meeting

Sydney Australia

Tuesday, 28th October 2014

2014 Annual General Meeting

Mr Gilman Wong
Chief Executive Officer



Focused on Performance and Growth

2014 DOSE SALES

↑
17.3%

8,561
DOSES
SOLD

2014 NET PROFIT AFTER TAX

↑
30.6%

2014 REVENUE

↑
33.7%

2001

2005

2010

2014


SIRTeX



Sales Revenue and Dose Sales


Sales revenue

\$ 000



Dose sales



Number of units



- APAC
- EMEA
- USA




FY 2014 Sales by Region




Dividends and Share Price

Dividends
Cents per share



SRX share price
\$ at 30th June each year



SIRFLOX study expanding the use of SIR-Spheres

The SIRFLOX Study

SIR-Spheres[®] + FOLFOX *versus* FOLFOX Alone

(with or without bevacizumab) in Patients with Unresectable Liver Metastases from Colorectal Cancer

Eligible Patients:

- Unresectable liver-only or liver-predominant colorectal cancer metastases
- No prior chemotherapy for advanced disease
- Fit for combination therapy and selective internal radiation therapy (SIRT)

Schema:



+ SIR-Spheres microspheres implanted day 3–4 of Cycle 1

* oxaliplatin administered at 60 mg/m² for Cycles 1–3 in the SIR-Spheres microspheres + FOLFOX arm ¹

^{C4/C1} at the investigator's discretion, bevacizumab may commence at Cycle 4 in the test arm and at Cycle 1 (or per institutional protocol) in the control arm

- Completed patient recruitment in March 2013
- Detailed results expected to be presented at ASCO meeting June 2015

SIRTeX

Investor “Lunch and Learn”

Understanding Cancer Clinical Studies

Professor Eric Van Cutsem



**INDEPENDENT EXPERT
DISCUSSION**

SYDNEY

MELBOURNE

10th & 11th December 2014



Optimising value and sustainable long-term growth

Sirtex three pillars

1

SIR-Spheres microspheres

- Fully exploit SIR-Spheres microspheres in:
 - Primary / secondary liver cancer
 - Kidney cancer and several other cancers.

2

Research & Development

- SIR-Spheres Evolution Program
- New technologies including:
 - Carbon cage nanoparticles
 - Coated nanoparticles
 - Radioprotector.


3

Mergers & Acquisitions

- Commercial ready technology that will add value and grow the business
- Seeking to capitalise on our capabilities and infrastructure.


Clinical programs are driving expanded use

Major clinical programs



New indications will also expand use

- RESIRT study investigating use of SIR-Spheres microspheres in treatment of primary kidney cancer
- Results to date are positive and justify expansion to define optimum dosage levels
- Plans to investigate use of SIR-Spheres microspheres for the treatment of cancers in other organs



Clinical Study in Renal Cell Carcinoma
Currently Enrolling Patients

The RESIRT Study

Pilot Study of Selective Internal Radiation Therapy (SIRT) with Yttrium-90 Resin Microspheres **SIR-Spheres**[®] in Patients with Renal Cell Carcinoma

SIRTeX

Three global manufacturing hubs



SIR-Spheres®
microspheres

Collaboration driving multiple innovations



Australian
National
University



THE UNIVERSITY OF
SYDNEY


Peter Mac 



National Cancer
Centre Singapore

SingHealth

Our vision is to make cancer a chronic disease



“Sirtex's vision is that one day cancer will no longer be a terminal disease that patients unfortunately die from, but a chronic disease that patients can successfully live with or be cured from.”





2014 Annual General Meeting



SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd